Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Recurrence × rovalpituzumab tesirine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 6 Neoplasms 3 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma 1 Head and Neck Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 60 Dexamethasone 46 Rituximab 32 Lenalidomide 32 Peripheral Blood Stem Cell Transplantation 29 fludarabine phosphate 26 Bortezomib 26 Filgrastim 25 Carboplatin 23 Radiotherapy 22 Etoposide 22 Melphalan 20 Paclitaxel 19 Busulfan 19 Cytarabine 18 Cyclosporine 18 pomalidomide 17 Whole-Body Irradiation 17 Mycophenolic Acid 17 Gemcitabine 17 Cisplatin 16 Bevacizumab 16 pembrolizumab 15 fludarabine 15 Methotrexate 13 Calcium Dobesilate 12 venetoclax 11 Tacrolimus 11 Nivolumab 11 Bendamustine Hydrochloride 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02674568 2021-07-30

TRINITY

AbbVie

Phase 2 Completed

342 enrolled 18 charts

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡